Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)

Letter Dermatology

A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab

Matteo Megna et al.

JOURNAL OF COSMETIC DERMATOLOGY (2023)

Article Dermatology

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials

Kenneth B. Gordon et al.

Summary: The study aimed to evaluate the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis. Pooled analysis of data from 8 clinical trials showed that bimekizumab was well tolerated with an increased incidence of mild to moderate oral candidiasis. No safety signals were observed, and there was no increased risk of adverse events with longer duration of bimekizumab exposure.

JAMA DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study

Luigi Gargiulo et al.

Summary: This study assessed the safety of biologic drugs in patients with psoriasis and viral hepatitis without antiviral prophylaxis. The results showed that biologic therapies, including anti-IL-23 drugs, appeared to be safe in patients seropositive for HCV or HBV core antibody.

DERMATOLOGY AND THERAPY (2022)

Add to Collection

Letter Dermatology

Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report

Mario Valenti et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis

Paolo Gisondi et al.

Summary: SIDeMaST contributed to the development of a guideline on systemic treatment of chronic plaque psoriasis, providing general treatment recommendations and detailed management and monitoring recommendations for specific drugs. It also offers guidance for specific clinical situations and information on treatment during the COVID-19 pandemic.

ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Kristian Reich et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Kenneth B Gordon et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Bimekizumab versus Adalimumab in Plaque Psoriasis

R. B. Warren et al.

Summary: The study found that bimekizumab was both noninferior and superior to adalimumab in reducing symptoms and signs of moderate-to-severe plaque psoriasis at week 16, but was associated with a higher frequency of oral candidiasis and diarrhea. Longer and larger trials are needed to further evaluate the efficacy and safety of bimekizumab compared to other agents in treating plaque psoriasis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Bimekizumab versus Secukinumab in Plaque Psoriasis

Kristian Reich et al.

Summary: In patients with moderate-to-severe psoriasis, treatment with bimekizumab resulted in greater skin clearance than treatment with secukinumab over 16 and 48 weeks but was associated with oral candidiasis. Longer and larger trials are needed to determine comparative effects and risks of interleukin-17 inhibitors in psoriasis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Medicine, General & Internal

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review

April W. Armstrong et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Allergy

β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis

Frank Kolbinger et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Add to Collection

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)

Related references

Export Citation

Share Paper